Ga 68 PSMA-11
- Generic Name
- Ga 68 PSMA-11
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C44H59GaN6O17
- CAS Number
- 1906894-20-9
- Unique Ingredient Identifier
- ZJ0EKR6M10
- Background
Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). Prostate cancer is one of the most commonly diagnosed cancers among men in Western...
- Indication
Gallium Ga-68 gozetotide, or Gallium Ga-68 PSMA-11, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer metastasis with:
- Associated Conditions
- Prostate-specific Membrane Antigen Positive Tumors
- Associated Therapies
- -
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 5
- Registration Number
- NCT06521775
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT06444412
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06004661
- Locations
- 🇪🇸
Novartis Investigative Site, El Palmar, Murcia, Spain
68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Target Recruit Count
- 110
- Registration Number
- NCT05847348
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, China
🇨🇳Nanfang Hospital Southern Medical University, Guangzhou, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC
- Conditions
- Interventions
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05670106
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05627778
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Peking, China
Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer
- Conditions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Morand Piert, MD
- Registration Number
- NCT05415228
68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05324332
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Clinical Use of 68Ga PSMA-11 PET/CT in Diagnosing, Staging and Restaging Prostate Cancer
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Dana Mathews
- Registration Number
- NCT05002465
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 48
- Registration Number
- NCT04886986
- Locations
- 🇺🇸
Brooklyn Methodist Hospital - New York Presbyterian, Brooklyn, New York, United States
🇺🇸Weill Cornell Medicine New York Presbyterian, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.